Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …
Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience
G Salles, M Barrett, R Foà, J Maurer, S O'Brien… - Advances in …, 2017 - Springer
Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised …
Background Treatment for patients with chronic lymphocytic leukaemia who are elderly or
who have comorbidities is challenging because fludarabine-based chemoimmunotherapies …
who have comorbidities is challenging because fludarabine-based chemoimmunotherapies …
Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options
S Sharma, KR Rai - Cancer, 2019 - Wiley Online Library
Within a period of just over a decade, managing chronic lymphocytic leukemia (CLL) has
become more effective and yet more challenging than ever before. The important …
become more effective and yet more challenging than ever before. The important …
[HTML][HTML] Role of microRNAs in chemoresistance
P Magee, L Shi, M Garofalo - Annals of translational medicine, 2015 - ncbi.nlm.nih.gov
Drug resistance is a major problem in the treatment of cancer patients. Resistance can
develop after prolonged cycles of chemotherapy or can be present intrinsically in the patient …
develop after prolonged cycles of chemotherapy or can be present intrinsically in the patient …
Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy
CD Herling, M Klaumünzer, CK Rocha… - Blood, The Journal …, 2016 - ashpublications.org
Genetic instability is a feature of chronic lymphocytic leukemia (CLL) with adverse
prognosis. We hypothesized that chromosomal translocations or complex karyotypes and …
prognosis. We hypothesized that chromosomal translocations or complex karyotypes and …
Role of non-coding RNA networks in leukemia progression, metastasis and drug resistance
Early-stage detection of leukemia is a critical determinant for successful treatment of the
disease and can increase the survival rate of leukemia patients. The factors limiting the …
disease and can increase the survival rate of leukemia patients. The factors limiting the …
[HTML][HTML] Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force
R Stauder, B Eichhorst, ME Hamaker, K Kaplanov… - Annals of …, 2017 - Elsevier
Chronic lymphocytic leukemia (CLL) mainly affects older people: the median age at
diagnosis is> 70 years. Elderly patients with CLL are heterogeneous with regard both to the …
diagnosis is> 70 years. Elderly patients with CLL are heterogeneous with regard both to the …
[HTML][HTML] Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study
AS Michallet, M Aktan, W Hiddemann, O Ilhan… - …, 2018 - ncbi.nlm.nih.gov
MABLE investigated the efficacy and safety of rituximab plus bendamustine or rituximab plus
chlorambucil in fludarabine-ineligible patients with chronic lymphocytic leukemia. Patients …
chlorambucil in fludarabine-ineligible patients with chronic lymphocytic leukemia. Patients …
Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician
Purpose Chemoimmunotherapy has been the standard of care for chronic lymphocytic
leukemia (CLL). However, the introduction of B-cell receptor (BCR) kinase inhibitors such as …
leukemia (CLL). However, the introduction of B-cell receptor (BCR) kinase inhibitors such as …